Gilead Sciences
GILDWhat is it worth to you? Move six assumptions and see what value per share you get, and where you stand against the price and other users.
At $168.98 (close on November 18) and with the other assumptions at their starting point, Gilead Sciences's sales would need to grow 11.7% a year for ten years; over its last decade, the median was 0.7%. Value it with your own assumptions.
Its accounts, year by year
| Year end | Sales | Growth | Margin |
|---|---|---|---|
| 12/2015 | 32,639 | — | 69.2% |
| 12/2016 | 30,390 | −6.9% | 59.3% |
| 12/2017 | 26,107 | −14.1% | 56.5% |
| 12/2018 | 22,127 | −15.2% | 40.9% |
| 12/2019 | 22,449 | 1.5% | 21.9% |
| 12/2020 | 24,689 | 10.0% | 19.1% |
| 12/2021 | 27,305 | 10.6% | 38.6% |
| 12/2022 | 27,281 | −0.1% | 29.2% |
| 12/2023 | 27,116 | −0.6% | 30.9% |
| 12/2024 | 28,754 | 6.0% | 8.7% |
| 12/2025 | 29,443 | 2.4% | 37.1% |
Sales in millions of dollars. The margin is the operating margin before stock pay, as a percentage of sales. Each row is a fiscal year, by the month it ends. Source: the reports Gilead Sciences files with the SEC, the US securities regulator; the latest is for the fiscal year ended December 31, 2025. See the report.
The model's starting point
- Sales growth, years 1 to 10: 2.4% a year.
- Sales growth after year 10: 2.5% a year.
- Operating margin, before stock pay: 30.9% of sales.
- Working capital needed to grow: −$5.4 per $100 of new sales.
- Capital spending: 2.1% of sales.
- Stock pay to employees: 2.4% of sales.
- Discount rate, the same for every company: 10%.
These are the six assumptions the page starts with; each user moves them as they see fit.
Reference points
They come from its accounts and its share price, compared with the median of the companies on grinboss. They are not a recommendation.
For
- Over ten years, its worst fall from a high was 36%; the median is 56%.
- Its share price moves less than the market: a five-year beta of 0.42; the median is 0.94.
- It makes $31 of operating profit for every $100 it sells, before stock pay; the median is $18.
- Growing brings it cash: it collects from its customers before it pays its suppliers.
Against
- Its margin has fallen over these years, from 59% to 31%.
- Its sales fell 1.0% a year on average over 10 years, from $32.6 billion to $29.4 billion; the median of grinboss companies is 6.6%.
- Its sales fell in 5 of the last 10 years: it is an uneven business.
- Its margin jumps from one year to the next: 13.1 points on average, and up to 28.4 in a single year; the median is 2.8 points.
Next results: February 9, 2027.
Other companies in its sector (Health Care)
HCA Healthcare (HCA) · Henry Schein (HSIC) · Idexx Laboratories (IDXX) · Illumina, Inc. (ILMN) · Incyte (INCY) · IQVIA (IQV) · Intuitive Surgical (ISRG) · Johnson & Johnson (JNJ) · All companies
Loading the model…